RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+16.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$838M
AUM Growth
+$27.2M
Cap. Flow
-$59.8M
Cap. Flow %
-7.14%
Top 10 Hldgs %
41.9%
Holding
75
New
19
Increased
15
Reduced
20
Closed
20
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$44.5M
2
BHC icon
Bausch Health
BHC
+$40.6M
3
CSLT
CASTLIGHT HEALTH, INC.
CSLT
+$34.3M
4
RAD
Rite Aid Corporation
RAD
+$23.2M
5
HCA icon
HCA Healthcare
HCA
+$22.6M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$48.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$34.3M
4
CELG
Celgene Corp
CELG
+$30.9M
5
AZN icon
AstraZeneca
AZN
+$30.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.72%
2 Miscellaneous 7.42%
3 Technology 2.82%
4 Communication Services 1.03%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALGN icon
26
Align Technology
ALGN
$10.3B
$15.3M 1.82%
+294,612
New +$16.5M
2014 Q1
0 quarters
ARAY icon
27
Accuray
ARAY
$20.9M
$14.2M 1.69%
1,475,360
-269,451
-15% -$2.55M
2013 Q3
2 quarters
NXTM
28
DELISTED
NxStage Medical Inc.
NXTM
$13.9M 1.66%
1,090,428
+399,658
+58% +$5.21M
2013 Q4
1 quarter
RCPT
29
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$13M 1.56%
310,727
-314,406
-50% -$13.5M
2013 Q3
2 quarters
OXFD
30
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$12.5M 1.5%
624,869
-321,588
-34% -$6.96M
2013 Q4
1 quarter
CSII
31
DELISTED
Cardiovascular Systems, Inc.
CSII
$12.4M 1.49%
+391,627
New +$12.9M
2014 Q1
0 quarters
PTLA
32
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$11.7M 1.4%
+452,194
New +$12.1M
2014 Q1
0 quarters
NSTG
33
DELISTED
NanoString Technologies, Inc.
NSTG
$10.9M 1.3%
528,070
-226,590
-30% -$4.32M
2013 Q3
2 quarters
ELGX
34
DELISTED
Endologix Inc
ELGX
$10.2M 1.22%
79,510
+47,937
+152% +$7.45M
2013 Q4
1 quarter
AKAO
35
DELISTED
Achaogen Inc
AKAO
$10.1M 1.21%
+653,700
New +$11.3M
2014 Q1
0 quarters
MODN icon
36
DELISTED
MODEL N, INC.
MODN
$8.64M 1.03%
854,378
+763,071
+836% +$8.5M
2013 Q4
1 quarter
FLXN icon
37
DELISTED
Flexion Therapeutics, Inc.
FLXN
$8.11M 0.97%
+493,183
New +$8.53M
2014 Q1
0 quarters
XOMA icon
38
DELISTED
Xoma
XOMA
$7.93M 0.95%
76,127
+37,068
+95% +$5.38M
2013 Q4
1 quarter
INGN icon
39
Inogen
INGN
$163M
$7.61M 0.91%
+460,923
New +$8.2M
2014 Q1
0 quarters
DSCI
40
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$7.58M 0.91%
+598,077
New +$7.73M
2014 Q1
0 quarters
BSTC
41
DELISTED
BioSpecifics Technologies Corp.
BSTC
$7.04M 0.84%
271,620
-14,437
-5% -$346K
2013 Q2
3 quarters
RXDX
42
DELISTED
Ignyta, Inc.
RXDX
$4.98M 0.59%
+600,000
New +$5.62M
2014 Q1
0 quarters
GERN icon
43
Geron
GERN
$765M
$4.41M 0.53%
+2,240,373
New +$8.93M
2014 Q1
0 quarters
AMBI icon
44
DELISTED
Ambit Biosciences Corp
AMBI
$3.35M 0.4%
367,602
-178,383
-33% -$1.89M
2013 Q4
1 quarter
VCRA
45
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$2.83M 0.34%
173,408
-110,992
-39% -$1.87M
2013 Q3
2 quarters
CERS icon
46
Cerus
CERS
$451M
$2.81M 0.34%
586,205
-1,469,369
-71% -$9.44M
2013 Q2
3 quarters
GNCA
47
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.28M 0.27%
+15,656
New +$1.92M
2014 Q1
0 quarters
HALO icon
48
Halozyme
HALO
$13.3B
$815K 0.1%
+64,167
New +$952K
2014 Q1
0 quarters
ISEE
49
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$692K 0.08%
19,374
-297,147
-94% -$10M
2013 Q4
1 quarter
CYNO
50
DELISTED
Cynosure, Inc. Class A
CYNO
$586K 0.07%
+20,000
New +$567K
2014 Q1
0 quarters
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2014 Portfolio in Review

As of Q1 2014, Redmile Group held 75 positions worth $838M, up 3.4% from $810M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $59.8M in Q1 2014, closing 20 positions and reducing 20 holdings. Its most notable exit was Gilead Sciences, an estimated $48.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Agilent Technologies worth $43.2M.

  • Redmile Group's largest Q1 2014 buy was Agilent Technologies: 1,080,646 shares worth $43.2M.
  • Redmile Group added most to HCA Healthcare in Q1 2014, an estimated $22.6M increase.
  • Redmile Group's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $72.5M.
  • Redmile Group fully exited Gilead Sciences in Q1 2014, selling an estimated $48.6M.
  • Redmile Group's ten largest holdings make up 42% of its $838M portfolio in Q1 2014.
  • Redmile Group opened 19 new positions and closed 20 in Q1 2014.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $838M.

Based on Redmile Group's 13F filing for Q1 2014, filed 15 May 2014.